China NMPA Drug Inspection - Shanghai Sairui Suzhou Pharmaceutical Co., Ltd. - Big hawthorn pill

The Hebei Provincial Drug Administration issued an announcement on December 30, 2019, detailing the results of drug quality supervision and sampling inspections conducted from October to December 2019. These inspections, part of the "2019 Hebei Province Drug Supervision and Sampling Inspection Plan," involved drug supervision and market supervision departments across the province. Multiple pharmaceutical companies were identified for producing or distributing substandard drugs. Hebei Sirui Pharmaceutical Co., Ltd., Anguo Yuanguang Pharmaceutical Co., Ltd., Hebei Wandong Pharmaceutical Co., Ltd., and Anguo Qiao Traditional Chinese Medicine Pieces Co., Ltd., had products, including Platycladus orientalis seed and Triticum aestivum, that failed "Appearance" standards. Hebei Qiyitang Pharmaceutical Co., Ltd.'s roasted jujube seeds failed "Content Determination," and Shanghai Sairui Suzhou Pharmaceutical Co., Ltd.'s Hawthorn pills were non-compliant for "weight difference." In response, regulatory authorities initiated immediate control measures, including sealing and seizing the affected products. The announcement mandates that relevant drug regulatory and market supervision departments investigate these illegal activities, publicize risk control measures within one week, and disclose the handling results for the implicated entities within three months. Furthermore, suspected counterfeit drugs require investigation and potential transfer to public security departments if criminal activity is found. All relevant findings must be reported to the Hebei Provincial Drug Administration's Inspection Division.